Hidekatsu Kuroda
Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 135 publications
Cell-type-specific actions of carnosic acid against Porphyromonas gingivalis-induced proliferation in liver cancer cells.
Journal: Journal of oral microbiology
Published: June 17, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 29, 2026
Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.
Journal: Hepatology international
Published: May 03, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Journal: Oncology
Published: April 19, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 07, 2026
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: April 03, 2026
Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: March 10, 2026
Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
Journal: Journal of gastroenterology
Published: February 21, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.
Journal: Hepatology (Baltimore, Md.)
Published: January 27, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
Journal: Journal of gastroenterology and hepatology
Published: January 19, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 13, 2026
Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach.
Journal: Journal of gastroenterology
Published: January 13, 2026
Last Updated: 09/26/2026